Jelena Saillard, MS, MBA

Lumateperone (ITI-007) for the Treatment of Schizophrenia: Overview of Placebo-Controlled Clinical Trials and an Open-label Safety Switching Study

Background: Lumateperone is a first-in-class agent in development for schizophrenia that acts synergistically through serotonergic, dopaminergic and glutamatergic systems.

Kimberly Vanover , PhD;

Jelena Saillard , MS, MBA;

Steven Glass , MD;

Susan Kazaouer , MD;

Michal Weingart , PhD;

Robert Davis , PhD;

Andrew Satlin , MD;

Sharon Mates , PhD;

03/01/2019

Results From a 12-Month Open-Label Safety Study of Lumateperone (ITI-007) in Patients With Stable Symptoms of Schizophrenia

Introduction: Lumateperone (ITI-007) is in development for the treatment of schizophrenia and bipolar depression. Lumateperone has a unique mechanism of action that simultaneously modulat...

Jelena Saillard , MS, MBA;

Christoph U. Correll , MD;

Suresh Durgam , MD;

Robert Davis , PhD;

Andrew Satlin , MD;

Sharon Mates , PhD;

Kimberly Vanover , PhD;

11/22/2019